Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review highlights that sexual dysfunction associated with 5-alpha-reductase inhibitors is recognized in clinical literature, with erectile dysfunction being the most common adverse effect, followed by ejaculatory dysfunction and decreased libido.

This study found that the combination of docetaxel, cisplatin, and 5-fluorouracil is active and feasible for treating squamous cell carcinoma of the head and neck, with dose level I recommended for further testing.

This study found that the progestins norgestimate and dienogest may help treat clinical hyperandrogeny in women by inhibiting skin 5 alpha-reductase activity with minimal androgenic potential.

This study found that the combination of MT-DADMe-ImmA and MTA selectively induced apoptosis in head and neck squamous cell carcinoma cell lines FaDu and Cal27, but not in normal fibroblasts or MTAP-deficient breast cancer cells.

This study found that finasteride significantly reduced serum dihydrotestosterone levels, confirming its efficacy as a 5a-reductase inhibitor, while Permixon showed no effect in healthy male volunteers.

This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.

This study suggests that botanical 5AR inhibitors like Serenoa repens and β-sitosterol may improve symptoms of androgenetic alopecia, with 60% of treated subjects showing improvement compared to placebo.

This study demonstrated that high oral doses of finasteride caused external genital abnormalities in male rhesus monkey fetuses, but intravenous doses did not lead to abnormalities.

This study found that 60% of men with mild to moderate androgenetic alopecia showed improvement after treatment with botanically derived 5AR inhibitors, suggesting these compounds may be effective, though larger trials are needed.

This study suggests that 5 mg/day oral finasteride may increase hair density and thickness in normoandrogenic Asian women with female pattern hair loss over 12 months.

This review discusses biochemical studies on 5 alpha-reductase and its inhibitors, comparing IC50 and Ki values for various compounds, but reports no new experimental results.

This study found that 4 weeks of finasteride treatment significantly decreased DHT levels in bald scalp to levels similar to hair-containing scalp in men with male pattern baldness.

This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.

In this study, females with 5 alpha-reductase-2 deficiency exhibited decreased body hair, normal sebum production, and delayed menarche, suggesting a role for DHT in hair growth and menstrual function.

This study identified multiple mutations in the 5 alpha-reductase-2 gene among male pseudohermaphrodites in the Dominican Republic, suggesting they do not share a common ancestry.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

Testosterone needs to be converted to DHT to reduce stress response in male rats.

This study found that spironolactone directly inhibits 5 alpha-reductase activity in hirsute women, resulting in decreased conversion of testosterone to dihydrotestosterone, which may contribute to its therapeutic effects.

This study observed that the ethyl acetate extract of Equisetum debile showed high activity against 5α-reductase and lipid peroxidation with no cytotoxicity on dermal papilla cells.

This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.

This review discusses recent advancements in understanding the use of 5 alpha-reductase inhibitors for benign prostatic hyperplasia, indicating that dual isoenzyme inhibitors like dutasteride may enhance treatment outcomes, but no new clinical results are presented.

This study found that overexpression of AKR1C3 in prostate cancer cells redirected androgen metabolism towards testosterone production, which facilitated cell proliferation, potentially reducing the effectiveness of finasteride treatment.

This study found that 5alpha-reductase type 1 localizes specifically to sebaceous glands in both normal and acne follicles, suggesting its role in sebum regulation.

This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.

In this animal study, administering testosterone alongside a 5α-reductase inhibitor counteracted testosterone's effects on prostate enlargement while preserving its beneficial effects on muscle and bone.

This study found that DPCP treatment led to cosmetically acceptable hair regrowth in 38% of patients with chronic severe alopecia areata, while adding 5% minoxidil showed no significant clinical benefit.

This review suggests that most mutations in the SRD5A2 gene show no clear genotype-phenotype correlation in 5-α-Reductase deficiency, although mutation location affects severity.

This review discusses the clinical and molecular history of 5-alpha reductase deficiency, highlighting its role in male sexual differentiation and potential therapeutic applications, but reports no new research outcomes.

This study found that chronic exposure to fadrozole or finasteride during frog development induced intersex individuals, which displayed different gene expression profiles depending on the chemical used.

This study found that 5-alpha-reductase inhibitors were associated with a reduced frequency of COVID-19 symptoms in males with androgenetic alopecia.